AA
BMY.RT

AlphaMark Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

AlphaMark Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-260
Closed – – 580
2020
Q4 		$0 Hold
260
– – ﹤0.01% 581
2020
Q3 		$1K Sell
260
-241,647
-100% -$690K ﹤0.01% 529
2020
Q2 		$866K Buy
241,907
+2,289
+1% +$8.26K 0.37% 51
2020
Q1 		$911K Buy
239,618
+415
+0.2% +$1.37K 0.5% 42
2019
Q4 		$720K Buy
+239,203
New +$622K 0.3% 59

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

AlphaMark Advisors's BMY.RT Position: Q1 2021 in Review

AlphaMark Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 260 shares.

AlphaMark Advisors first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $911K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • AlphaMark Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • AlphaMark Advisors sold 260 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • AlphaMark Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • AlphaMark Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $911K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on AlphaMark Advisors's 13F filing for Q1 2021, filed 29 Apr 2021.